First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

Special Issues and Supplements —May 16, 2022
The Lynx Group: 2022 Ask The Expert M Choi.pdf
Please Click the Issue to Download

Introduction

This resource provides insights from a medical oncologist who specializes in gastric cancer and esophageal cancer. Here you will find information on the expanded analyses of efficacy and safety at a 24-month follow-up from Checkmate 649, a multicenter, randomized, phase 3, open-label study that evaluated OPDIVO plus capecitabine and oxaliplatin (CapeOX) or OPDIVO plus fluorouracil, leucovorin, and oxaliplatin (FOLFOX) compared with CapeOX or FOLFOX alone as first-line therapy in patients with previously untreated, unresectable, advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Download to Continue Reading

Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country